ReviewMolecular biology reports2025
Potential use of plant secondary metabolites in the treatment of allergic respiratory diseases (ARDs).
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The occurrence of allergic respiratory diseases (ARDs) is increasing worldwide due to hypersensitivity to foreign allergens. Around 40% of the global population is affected by ARDs which are exacerbated by environmental pollution. Furthermore, prolonged ARDs-associated symptoms reduce quality of life and increase the risk of neurological disorders like depression, anxiety disorder, and dementia through oxidative stress-induced neuroinflammation. Recently, plant secondary metabolites (PSMs) have emerged as novel dietary therapeutics, which exhibit potent antioxidant and antiallergic capabilities in treating ARDs. These bioactive compounds, have antimicrobial, antiviral, and antiallergic properties, making them particularly useful in treating respiratory diseases. This review summarizes and discusses the mechanisms of ARDs and how PSMs could be alternative therapeutics for treating ARDs, as well as prospects.
Indexed as
Identifiers
40569507What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.